A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Adagio Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 44,400 shares of ADGI stock, worth $146,964. This represents 0.0% of its overall portfolio holdings.

Number of Shares
44,400
Holding current value
$146,964
% of portfolio
0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
N/A
44,400 New
44,400 $146,000
Q2 2022

Aug 15, 2022

BUY
$2.54 - $4.52 $29,464 - $52,431
11,600 New
11,600 $38,000

Others Institutions Holding ADGI

About Adagio Therapeutics, Inc.


  • Ticker ADGI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 108,831,000
  • Market Cap $505M
  • Description
  • Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatmen...
More about ADGI
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.